Brucellosis, which affects the genitourinary system in rate of 2–20%, is a multiorgan infectious disease. Twelve patients were diagnosed as having brucellar orchitis serologically, clinically and ultrasonographically. In 2 patients, Brucella melitensis was isolated in blood cultures. All the patients were working in cattle dealing. They were treated with 600 mg/day rifampicin plus 200 mg/day doxycycline for 6 weeks and followed up during 1 year. They recovered clinically within 3 weeks. Although they did not have any symptoms or findings, in 4 patients, serological titers did not return to normal after 6 weeks. In 2 of these patients, relapse was seen in the 6th and 8th months, respectively. These 2 patients recovered with 1 g/day ciprofloxacin plus 2 g/day tetracycline for 6 weeks. Relapse did not occur again. Conclusively, brucellosis must be considered as a cause of orchitis in especially endemic regions where cattle dealing is widespread. The patients must be followed for relapse during at least 1 year.

Keywords:
Brucellosis, Orchitis, Relapse
This content is only available via PDF.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.